Redifferentiation-facilitated radioiodine therapy in thyroid cancer - Archive ouverte HAL Access content directly
Journal Articles Endocrine-Related Cancer Year : 2021

Redifferentiation-facilitated radioiodine therapy in thyroid cancer

(1) , (1) , (2) , (1) , (1)
1
2

Abstract

Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary data obtained in a small series of patients were encouraging and this strategy might become an alternative treatment in those patients with a druggable mutation that induces a stimulation of the MAP kinase pathway. This is an active field of research to answer many still unresolved questions.
Fichier principal
Vignette du fichier
ERCREIFFERENTIATION_24122020_NAslx(1).pdf (562.57 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03445754 , version 1 (25-11-2021)

Identifiers

Cite

Livia Lamartina, Nadège Anizan, Corinne Dupuy, Sophie Leboulleux, Martin Schlumberger. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocrine-Related Cancer, 2021, 28 (10), pp.T179-T191. ⟨10.1530/ERC-21-0024⟩. ⟨hal-03445754⟩
28 View
21 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More